Autor segons l'article: Rehues, P; Girona, J; Guardiola, M; Plana, N; Scicali, R; Piro, S; Muñiz-Grijalvo, O; Díaz-Díaz, JL; Recasens, L; Pinyol, M; Rosales, R; Esteban, Y; Amigó, N; Masana, L; Ibarretxe, D; Ribalta, J
Departament: Medicina i Cirurgia Ciències Mèdiques Bàsiques
Autor/s de la URV: Girona Tell, Josefa / Guardiola Guionnet, Montserrat / Ibarretxe Gerediaga, Daiana / Masana Marín, Luis / Plana Gil, Núria / Rehues Masip, Pere / Ribalta Vives, Josep / ROSALES RIBAS, ROSER
Paraules clau: Pcsk9 Of-function mutations Ldl Inflammation Glycoproteins Apolipoprotein c-iii Alirocumab triglycerides reactive protein plasma lipoproteins ldl-cholesterol ldl inflammatory response inflammation glycoproteins glyca evolocumab apolipoprotein c-iii alirocumab
Resum: Highlights: What are the main findings? PCSK9 inhibition significantly reduces 1H-NMR glycoprotein signals and does not affect hsCRP levels. Apolipoprotein C-III and triglycerides are also decreased by iPCSK9. The decrease in glycoproteins correlates with the decrease in apoC-III and TG. What is the implication of the main finding? PCSK9 inhibition significantly reduces inflammation Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001). It also increased apoA-I (2.05%, p = 0.043) and HDL cholesterol levels (11.58%, p < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, p < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III.
Àrees temàtiques: Zootecnia / recursos pesqueiros Spectroscopy Saúde coletiva Química Psicología Physical and theoretical chemistry Organic chemistry Odontología Nutrição Molecular biology Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Interdisciplinar Inorganic chemistry Geociências Farmacia Engenharias iv Engenharias ii Engenharias i Educação física Computer science applications Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciências agrárias i Ciência de alimentos Ciência da computação Chemistry, multidisciplinary Catalysis Biotecnología Biodiversidade Biochemistry & molecular biology Astronomia / física
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: daiana.ibarretxe@urv.cat luis.masana@urv.cat pere.rehues@urv.cat josefa.girona@urv.cat pere.rehues@urv.cat josefa.girona@urv.cat montse.guardiola@urv.cat josep.ribalta@urv.cat
Identificador de l'autor: 0000-0002-0789-4954 0000-0002-6267-8779 0000-0002-6267-8779 0000-0002-9696-7384 0000-0002-8879-4719
Data d'alta del registre: 2024-08-03
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.mdpi.com/1422-0067/24/3/2319
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: International Journal Of Molecular Sciences. 24 (3):
Referència de l'ítem segons les normes APA: Rehues, P; Girona, J; Guardiola, M; Plana, N; Scicali, R; Piro, S; Muñiz-Grijalvo, O; Díaz-Díaz, JL; Recasens, L; Pinyol, M; Rosales, R; Esteban, Y; A (2023). PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. International Journal Of Molecular Sciences, 24(3), -. DOI: 10.3390/ijms24032319
DOI de l'article: 10.3390/ijms24032319
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2023
Tipus de publicació: Journal Publications
Repositori URV